Abstracts tagged "BAFF"

Abstract Number: 1126 • 2015 ACR/ARHP Annual Meeting
Pyrrolopyrimidine Derivatives That Inhibit BAFF Binding to Its Receptor, BR3, Decrease IgG Production By B Cells in Vitro and in Vivo Model of Autoimmune Diseases
Keiko Yoshimoto¹, Eriko Ishioka², Ayumi Nishikawa¹, Katsuya Suzuki¹, Kunio Sugahara³ and Tsutomu Takeuchi⁴, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal medicine, Keio University School of Medicine, Tokyo, Japan, ³Department I, Immunology, Pharmacology Research laboratories I, Research Division, Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan, ⁴Keio University School of Medicine, Tokyo, Japan
Background/Purpose: We have found that the expression level of BAFF receptor (BR3) is abnormally enhanced in peripheral monocytes of patients with pSS, and BAFF robustly…
Abstract Number: 2696 • 2014 ACR/ARHP Annual Meeting
Relationship Between Soluble sCD23 and B Cell Activation Factor in Patients with Systemic Lupus Erythematosus before and after Rituximab
Laura Heretiu^1,2, Maria J. Leandro³, Venkat Reddy⁴, David A. Isenberg⁵ and Geraldine Cambridge³, ¹Medicine, Centre for Rheumatology, University College London, London, United Kingdom, ²Rheumatology and Internal Medicine, 'Sf. Maria' Clinical Hospital, Bucharest, Romania, ³Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁴Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, ⁵Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom
Background/Purpose CD23 is the low-affinity receptor for IgE (FceRII). The soluble form, sCD23 is released into the circulation and in vitro this is consistent with…
Abstract Number: 2695 • 2014 ACR/ARHP Annual Meeting
Alterations in B Cell Subsets and BAFF Levels in Autoimmune Rheumatic Diseases Treated with B Cell Depletion Therapy: Rituximab
Pamela M.K Lutalo¹, David P. D'Cruz² and Jo Spencer³, ¹Peter Gorer Department of Immunobiology, King's College London School of Medicine, London, United Kingdom, ²Louise Coote Lupus Unit, Guy's and St Thomas' Hospital NHS Foundation Trust, London, United Kingdom, ³Peter Gorer Department of Immunobiology, King's College London, School of Medicine, London, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) and granulomatosis with polyangiitis (GPA) are autoimmune diseases which develop secondary to immune self-tolerance failure. Both diseases are characterised in…
Abstract Number: 1974 • 2014 ACR/ARHP Annual Meeting
Sex Steroids, Interleukin-1, and Interleukin-10 Inhibit interferon–gamma (IFN-γ) Induced B Cell Activating Factor of the Tumor Necrosis Factor Family (BAFF) in Human Synovial Fibroblasts
Georg Pongratz¹, Marina Bäuml², Tanja Späth², Rainer Straub³ and Torsten Lowin², ¹Internal Medicine I, University Hospital Regensburg, Regensburg, Germany, ²University Hospital Regensburg, Regensburg, Germany, ³Internal Medicine, University Hospital Regensburg, Regensburg, Germany
Background/Purpose B cell activating factor of the tumor necrosis factor family (BAFF) is a cytokine important for the stimulation and survival of autoreactive B cells…
Abstract Number: 1640 • 2014 ACR/ARHP Annual Meeting
Cyclophosphamide Diminishes Plasmablasts and Transitional B Cells and Suppresses Autocrine Production of B Cell Activating Factor of Tumor Necrosis Factor Family (BAFF) in These Cells in Patients with Systemic Lupus Erythematosus
Yuko Okamoto¹, Yasuhiro Katsumata¹, Yasushi Kawaguchi¹, Manabu Kawamoto¹, Takahisa Gono¹, Masanori Hanaoka¹, Tomoaki Higuchi¹, Hidenaga Kawasumi¹ and Hisashi Yamanaka², ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose . B cell activating factor of tumor necrosis factor family (BAFF) is a positive regulator of B cell function and expressed in dendritic cells,…
Abstract Number: 857 • 2014 ACR/ARHP Annual Meeting
Amelioration of Systemic Lupus Erythematosus (SLE) in NZM 2328 Mice By Selectively Blocking Engagement of Two BAFF Receptors
Chaim O. Jacob, Ning Yu and William Stohl, Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA
Background/Purpose: BAFF, a potent B cell survival factor, is an established therapeutic target in SLE, with the anti-BAFF antibody, belimumab, being FDA-approved for the treatment…
Abstract Number: 1604 • 2013 ACR/ARHP Annual Meeting
Effects Of Chronic Treatment With Blisibimod, An Inhibitor Of B Cell Activating Factor, On Renal and Inflammation Biomarkers In Patients With Systemic Lupus Erythematosus: Observations From The Placebo-Controlled Pearl-SC and Open-Label Extension Studies
Richard A. Furie¹, Matthew Thomas², Alvina Chu³, Renee S. Martin³, Colin Hislop³ and Morton A. Scheinberg⁴, ¹The Feinstein Institute for Medical Research and North Shore-Long Island Jewish Health System, Lake Success, NY, ²Health and Research Centre, Trivandrum, Kerala, India, ³Anthera Pharmaceuticals Inc, Hayward, CA, ⁴Rheumatology Hospital Abreu Sodre Pesquisa Clínica, São Paulo, Brazil
Background/Purpose: To evaluate the effects of subcutaneously-administered blisibimod on renal and inflammation biomarkers in patients with SLE during the phase 2b clinical trial PEARL-SC (NCT01162681)…
Abstract Number: 1562 • 2013 ACR/ARHP Annual Meeting
Elevated Serum B-Cell Activating Factor (BAFF/BlyS) Characterises Disease Relapse Following Rituximab In Systemic Lupus Erythematosus
Lucy M. Carter¹, David A. Isenberg² and Michael R. Ehrenstein³, ¹University College London, London, United Kingdom, ²Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ³Rheumatology Research, University College London, London, United Kingdom
Background/Purpose: Numerous reports suggest that B cell depletion therapy (BCDT) using rituximab is effective in patients with systemic lupus erythematosus (SLE). However, two major trials…
Abstract Number: 722 • 2013 ACR/ARHP Annual Meeting
BAFF Promotes T Follicular Helper Cell Development and Germinal Center Generation In Mice
Song Guo Zheng¹, Maogeng Chen¹, Qiang Li² and William Stohl³, ¹Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, ²University of Southern California Keck School of Medicine, Los Angeles, CA, ³Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA
Background/Purpose: BAFF (B cell activating factor belonging to the TNF family) promotes B cells maturation in germinal center. The generation of germinal center depends on…
Abstract Number: 511 • 2013 ACR/ARHP Annual Meeting
Salivary Gland Lymphocyte Pattern Associated With Response To Belimumab In Primary sjogren’ssyndrome: Results Of The Beliss Study
Raphaèle Seror¹, Thierry Lazure², Frederic Desmoulins³, Stephan Pavy⁴, Corinne Miceli-Richard⁵, Gabriel Baron⁶, Philippe Ravaud⁷ and Xavier Mariette⁸, ¹Rheumatology, Université Paris Sud, Le Kremlin Bicêtre, France, ²Pathology, INSERM U1012 - Université Paris XI, Le Kremlin Bicêtre, France, ³Rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, Le Kremlin Bicetre, France, ⁴Rheumatology, Hopital Bicetre, Paris, France, ⁵Rheumatology Department, Université Paris-Sud 11, Bicêtre Hospital,, Kremlin Bicêtre, France, ⁶Hotel Dieu University Hospital Paris, Epidemiology, Paris, France, ⁷Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ⁸Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France
Background/Purpose: To address the change in labial salivary gland (LSG) inflammation after Belimumab (biological treatment inhibiting soluble BAFF/BLyS) therapy in pSS patients and identify predictor…
Abstract Number: 2796 • 2013 ACR/ARHP Annual Meeting
Effects Of BAFF Inhibition On B Cell Selection In Murine SLE
Alexis Boneparth^1,2, Ramalingam Bethunaickan³, Weiqing Huang⁴ and Anne Davidson⁴, ¹Pediatrics, The Children's Hospital at Montefiore, Bronx, NY, ²Feinstein Institute for medical Research, Manhasset, NY, ³Autoimmunity, Feinstein Institute for Medical Research, Manhasset, NY, ⁴Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: BAFF inhibition is a new B cell targeted therapy approved for the treatment of moderately active SLE. Although BAFF regulates selection of naïve autoreactive…
Abstract Number: 2610 • 2013 ACR/ARHP Annual Meeting
A New Pathogenic Role Of BAFF As a Critical Mediator Of Skin and Lung Fibrosis In Experimental Bleomycin-Induced Pulmonary Fibrosis, Systemic Sclerosis and Idiopathic Pulmonary Fibrosis
Antoine Francois¹, Pascal Schneider², Anne Davidson³, Emmanuel Chatelus⁴, Jérôme Avouac⁵, Yannick Allanore⁶, Bérengère Villeret⁷, Aurélie Gombault⁷, Paméla Gasse⁸, Sylvain Marchand Adam⁹, Bernhard Ryffel¹⁰, Siamak Bahram¹¹, Philippe Georgel¹², Jean Sibilia¹³, Isabelle Couillin⁸ and Jacques-Eric Gottenberg¹⁴, ¹Laboratory of Physiopathology of Arthritises, University of Strasbourg, Illkirch-Strasbourg, France, ²Department of Biochemistry, University of Lausanne, Lausanne, Switzerland, ³Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY, ⁴Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁵Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, ⁶Rheumatology, Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, ⁷Molecular Immunology and Embryology, University of Orleans and National Center for Scientific Research, Orléans, France, ⁸Molecular Immunology and Embryology, University of Orleans and National Center for Scientific Research, Orleans, France, ⁹Francois Rabelais University, National institute of the health and the medical research, Tours, France, ¹⁰UMR6218, Molecular Immunology, University and CNRS, 3b rue de la Ferollerie, Orleans, France, ¹¹Fédération of Translational Medicine of Strasbourg (FMTS), Immunorhumatology Molécular, Strasbourg, France, ¹²Université de Strasbourg, Laboratoire d'ImmunoGénétique Moléculaire Humaine, Strasbourg, France, ¹³Rheumatology, CHU Hautepierre, Strasbourg, France, ¹⁴Strasbourg University Hospital, Strasbourg, France
Background/Purpose: Interstitial pneumonitis and lung fibrosis are frequent systemic complications of inflammatory arthritides, including systemic sclerosis (SSc), rheumatoid arthritis, or primary Sjögren’s syndrome. B lymphocytes…
Abstract Number: 2518 • 2013 ACR/ARHP Annual Meeting
Only BAFF mRNA, Not BAFF Protein Level In Blood, Is Associated With SLE Activity Over One Year
Eric Zollars¹, Hong Fang², Jadwiga Bienkowska³, Julie Czerkowicz⁴, Ann Ranger⁴, Norm Allaire⁵, Alice Thai⁴, Jeff Browning⁶, Laurence S. Magder⁷ and Michelle Petri², ¹Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Translational Medicine, Biogen Idec Inc., Cambridge, MA, ⁴Biogen Idec Inc, Cambridge, MA, ⁵Biogen Idec Inc., Cambridge, MA, ⁶Boston University School of Medicine, Boston, MA, ⁷Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD
Background/Purpose: B-cell–activating factor (BAFF; also known as B lymphocyte stimulator or BLyS) is a prominent factor in the selection and survival of B cells. BAFF…
Abstract Number: 1840 • 2013 ACR/ARHP Annual Meeting
Increased Expression of BAFF Receptor On Monocytes Is a Contributory Factor of Hypergammaglobulinemia in Patients With Primary Sjögren’s Syndrome
Keiko Yoshimoto¹, Maiko Tanaka², Masako Kojima², Hideko Ogata², Eriko Ishioka³, Ayumi Nishikawa², Katsuya Suzuki¹, Hideto Kameda¹, Tohru Abe⁴ and Tsutomu Takeuchi⁵, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Division of Rheumatology, Department of Internal medicine, Keio University School of Medicine, Tokyo, Japan, ⁴Dept Int Med Saitama Med Ctr, Saitama Medical School, Kawagoe-shi Saitama, Japan, ⁵Keio University School of Medicine, Tokyo, Japan
Background/Purpose: BAFF (B cell stimulation factor belonging to TNF family) is a cytokine which is mainly produced by monocytes, dendritic cells and T cells. We…
Abstract Number: 1732 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Subcutaneous Administration Of Tabalumab, An Anti-B Cell Activating Factor Monoclonal Antibody, In Rheumatoid Arthritis: Results From a Phase 3 Multicenter, Randomized, Double-Blind Study
MC Genovese¹, Gregg J. Silverman², Paul Emery³, Ramesh Gupta⁴, Anne Gill⁵, Wendy J. Komocsar⁵, Melissa Veenhuizen⁵, Li Xie⁵, Pierre-Yves Berclaz⁵ and Chin Lee⁵, ¹Division of Rheumatology, Stanford University, Palo Alto, CA, ²Rheumatology, NYU School of Medicine, New York, NY, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Private Practice, Memphis, TN, ⁵Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Tabalumab is a monoclonal antibody that neutralizes membrane-bound and soluble B cell activating factor (BAFF). These interim analyses evaluated the efficacy and safety of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].